February 16, 2015 | The world’s largest pharmaceutical company, Novartis has expressed increased interest in investing in Israeli companies. Novartis invested $35 million in Israeli startup Gamida Cell as well as companies like BioLineRX, which will develop emerging Israeli technologies for Novartis. Novartis Pharmaceuticals Division head is David Epstein, who directs strategy as well as investments in Israeli pharmaceutical and biomedical companies.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Israeli Startup Rings Closing Bell At Nasdaq in NYC
March 28, 2024
Israeli, US Companies Unite To Make More Milk From Mushrooms
March 27, 2024
Facebook comments